A Phase 3 interventional study of AD109 and Placebo in OSA, sponsored by Apnimed. Completed at 64 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Apnimed · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Sleep Apnea, Obstructive by Apnimed — 1 open to participants now, 1 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Apnimed.
Among the 13 studies in Sleep Apnea, Obstructive by Apnimed, this one is the 2nd largest by enrollment, is one of 3 that started in 2023, is one of 3 in phase 3, and was the 10th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →1 of the 13 studies in Sleep Apnea, Obstructive by Apnimed is open now, in 2 countries. Recruiting first, the newest first:
Apnimed · Sites in United States, Canada
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 3
First in 2019; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 660 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 60 across the 13 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Apnimed is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 8 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Sleep Apnea, Obstructive by Apnimed, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AD109
Drug: Placebo
Aroxybutynin 2.5 mg/atomoxetine 75 mg tablet, administered orally once daily at bedtime (Weeks 2-51). Week 1 run-in: aroxybutynin 2.5 mg/atomoxetine 37.5 mg tablet.
Matching placebo tablet administered orally once daily at bedtime for 51 weeks, with run-in and target dose matched to active arm packaging.
Change From Baseline in Apnea-Hypopnea Index (AHI)
AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%.
Time frame: 6 months
| Milestone | AD109 | Placebo |
|---|---|---|
| Started | 329 | 331 |
| Completed | 250 | 274 |
| Not completed | 79 | 57 |
| Withdrew: Adverse event | 12 | 7 |
| Withdrew: Lost to follow-up | 24 | 20 |
| Withdrew: Physician decision | 2 | 7 |
| Withdrew: Withdrawal by subject | 33 | 19 |
| Withdrew: Site terminated by sponsor | 3 | 2 |
| Withdrew: Other/not reported | 5 | 2 |
AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%.
| events/hr | AD109 | Placebo |
|---|---|---|
| Full Analysis Set (Treatment Policy Estimand) | -3.88 (-5.37 to -2.39) | 0.21 (-1.24 to 1.65) |
| While-on-Treatment population | -5.83 (-7.51 to -4.15) | -0.02 (-1.55 to 1.50) |
Collected over from enrollment until the end of follow-up, up to 53 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AD109 | 0/328 (0%) | 5/328 (1.5%) | 220/328 (67.1%) |
| Placebo | 0/327 (0%) | 10/327 (3.1%) | 122/327 (37.3%) |
| Event | AD109 | Placebo |
|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/328 | 1/327 |
| Cervical radiculopathyNervous system disorders | 0/328 | 1/327 |
| DizzinessNervous system disorders | 0/328 | 1/327 |
| Ischaemic strokeNervous system disorders | 0/328 | 1/327 |
| Deep vein thrombosisVascular disorders | 0/328 | 1/327 |
| Acute myocardial infarctionCardiac disorders | 0/328 | 1/327 |
| Angina pectorisCardiac disorders | 0/328 | 1/327 |
| Atrial fibrillationCardiac disorders | 0/328 | 1/327 |
| Coronary artery diseaseCardiac disorders | 0/328 | 1/327 |
| Myocardial infarctionCardiac disorders | 0/328 | 1/327 |
| Event | AD109 | Placebo |
|---|---|---|
| Dry mouthGastrointestinal disorders | 130/328 | 31/327 |
| Middle insomniaPsychiatric disorders | 44/328 | 13/327 |
| NauseaGastrointestinal disorders | 43/328 | 7/327 |
| Initial insomniaPsychiatric disorders | 32/328 | 12/327 |
| Urinary hesitationRenal and urinary disorders | 27/328 | 2/327 |
| Upper respiratory tract infectionInfections and infestations | 19/328 | 26/327 |
| COVID-19Infections and infestations | 14/328 | 25/327 |
| SomnolenceNervous system disorders | 24/328 | 12/327 |
| HeadacheNervous system disorders | 22/328 | 23/327 |
| DyspepsiaGastrointestinal disorders | 20/328 | 7/327 |
The Full Analysis Set includes all randomized participants who were not from the terminated site 1308 and received at least 1 dose of IMP.
| Age, Continuous(years) | AD109 | Placebo | Total |
|---|---|---|---|
| Mean | 57.2 ± 10.26 | 57.4 ± 10.72 | 57.3 ± 10.49 |
| Sex: Female, Male(Participants) | AD109 | Placebo | Total |
|---|---|---|---|
| Female | 160 | 138 | 298 |
| Male | 164 | 188 | 352 |
| Race (NIH/OMB)(Participants) | AD109 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 5 | 5 | 10 |
| Asian | 11 | 9 | 20 |
| Native Hawaiian or Other Pacific Islander | 3 | 3 | 6 |
| Black or African American | 58 | 53 | 111 |
| White | 238 | 246 | 484 |
| More than one race | 3 | 4 | 7 |
| Unknown or Not Reported | 6 | 6 | 12 |
| Baseline AHI4 group(Participants) | AD109 | Placebo | Total |
|---|---|---|---|
| <15 | 119 | 125 | 244 |
| 15 - 30 | 109 | 104 | 213 |
| >30 | 96 | 97 | 193 |
| Baseline AHI4(events/hr) | AD109 | Placebo | Total |
|---|---|---|---|
| Mean | 24.03 ± 16.692 | 24.69 ± 18.735 | 24.36 ± 17.736 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2023 to primary completion in May 2025, 20 months.
Results were first posted in Nov 2026, 1 year 5 months after primary completion.
Of 27 phase 3 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 32. This study's 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AD109
Apnimed